Abstract:
:Imatinib has pronounced antileukemic activity in Ph+ALL, although responses are usually short. To determine whether imatinib may facilitate allogeneic SCT in relapsed or refractory Ph+ALL, we evaluated 46 consecutive, not previously transplanted patients who were enrolled in phase II studies of imatinib. Of 30 patients eligible for SCT, 22 (73%) were actually transplanted. Ten patients were in complete hematologic remission (CHR) (n = 5) or had a complete marrow response (CMR) (n = 5) at the time of SCT, 12 patients had again relapsed or were refractory. After SCT, 18 patients were in complete remission, one patient was refractory, three patients died prior to response assessment. Seven patients (32%) are in ongoing complete remission with a median follow-up of 9.4 (range 1.7-23.8) months. Seven patients (32%) relapsed a median of 5.2 months after SCT. Transplant-related mortality (TRM) was 36%. Probability of disease-free survival (DFS) is 25.5 +/- 9.8% overall and 51.4 +/- 17.7% when SCT was performed in CHR or CMR, compared with 8.3 +/- 8% for SCT during overt leukemia (P = 0.06). In conclusion, imatinib is a well-tolerated salvage therapy prior to allogeneic SCT in patients with Ph+ALL, but requires that SCT be performed within a few weeks of starting treatment to avoid resistance. Disease status at time of transplantation is an important determinant of DFS and TRM.
journal_name
Leukemiajournal_title
Leukemiaauthors
Wassmann B,Pfeifer H,Scheuring U,Klein SA,Gökbuget N,Binckebanck A,Martin H,Gschaidmeier H,Hoelzer D,Ottmann OGdoi
10.1038/sj.leu.2402770subject
Has Abstractpub_date
2002-12-01 00:00:00pages
2358-65issue
12eissn
0887-6924issn
1476-5551journal_volume
16pub_type
临床试验,杂志文章相关文献
LEUKEMIA文献大全abstract::Clinical outcomes for multiple myeloma (MM) are highly heterogeneous and it is now clear that pivotal genetic events are the primary harbingers of such variation. These findings have broad implications for counseling, choice of therapy and the design and interpretation of clinical investigation. Indeed, as in acute le...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2404516
更新日期:2007-03-01 00:00:00
abstract::We established the continuous growth of WEHI-3B D+ cells in protein-free chemically defined F-12 medium by stepwise decreases in the concentration of fetal calf serum. This cell line, designated as WEHI-3B-Y1, has now been propagated in protein-free F-12 medium for 3 years. The population-doubling time of the cells in...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1990-10-01 00:00:00
abstract::Acute lymphoblastic leukemia (ALL) is the most frequent cancer encountered in children. Little is known about the molecular pathology of childhood T cell ALL. Oncogenesis is a multistep process that involves alterations in proto-oncogenes and tumor suppressor genes. Recently, a mutator phenotype detectable by microsat...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2400650
更新日期:1997-06-01 00:00:00
abstract::The authors analyzed twelve patients with symptomatic essential throthrombocythemia (E.T.) diagnosed from 1983 to 1991. Haemorrhagic and thrombotic phenomena were the main presenting features. Treatment consisted mostly of alpha-interferon (IFN-alpha 2b) subcutaneously in dosage ranging from 3 to 5 MU/m2 and hydroxyur...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1992-01-01 00:00:00
abstract::The monitoring of chimerism by PCR has become a routine diagnostic approach in patients after allogeneic bone marrow or peripheral blood stem cell transplantation. Nevertheless, a temporal correlation between molecular and hematologic assessment of engraftment has not been clearly established. To address this issue, a...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1999-12-01 00:00:00
abstract::Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved due to advances in drug development and rational treatment intervention strategies. Despite these significant advances there are still unanswered questions on patient management regarding how to more reliably predict treatment failur...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/s41375-019-0512-y
更新日期:2019-08-01 00:00:00
abstract::Two proteins that have been correlated with the occurrence of multidrug resistance in acute myeloid leukemia (AML) are P-glycoprotein (Pgp) and the major vault protein (Mvp/LRP). With the purpose of further quantifying the potential contributions of Pgp-mediated drug efflux and Mvp/LRP to drug resistance in AML we hav...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401331
更新日期:1999-02-01 00:00:00
abstract::To characterise the genetics of splenic marginal zone lymphoma (SMZL), we performed whole exome sequencing of 16 cases and identified novel recurrent inactivating mutations in Kruppel-like factor 2 (KLF2), a gene whose deficiency was previously shown to cause splenic marginal zone hyperplasia in mice. KLF2 mutation wa...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2014.330
更新日期:2015-05-01 00:00:00
abstract::Transplantation of normal and malignant human hematopoietic cells into severe combined immunodeficient (SCID) mice allows for evaluation of long-term growth abilities of these cells and provides a preclinical model for therapeutic interventions. However, large numbers of cells are required for successful engraftment i...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2400694
更新日期:1997-07-01 00:00:00
abstract::It has been proposed that adoptive immunotherapy, for the treatment of relapsed AML, with cytotoxic T lymphocytes which show a relative specificity for the leukemic cells may have the advantage of maximizing the beneficial anti-leukemic effect whilst minimizing the probability of graft-versus-host disease. In this stu...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402013
更新日期:2001-02-01 00:00:00
abstract::Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML) patients; however, responses to frontline imatinib are variable. The human organic cation transporter 1 (OCT1; SLC22A1) has been reported to be the main influx transporter involved in imatinib uptake into CML cells. Furthermore...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/leu.2015.170
更新日期:2015-10-01 00:00:00
abstract::We have developed a method to quantify topoisomerase (topo) II activities in partially purified nuclear extracts from human leukemia cells. By virtue of their different pH optima in the reaction buffer, two different topo II activities were found with activity optima at pH 7.9 and at pH 8.9 under high stringency condi...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1996-07-01 00:00:00
abstract::CD31/PECAM-1 (platelet endothelial cell adhesion molecule-1) is a 130 kDa integral membrane protein of the immunoglobulin gene superfamily with the distinctive feature of being expressed on several cell types associated with the vascular compartment. In the present study we report a novel, unique CD31 mAb termed IP28A...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1996-08-01 00:00:00
abstract::Hematopoiesis is orchestrated by interactions between hematopoietic stem/progenitor cells (HSPCs) and stromal cells within bone marrow (BM) niches. Side population (SP) functionality is a major characteristic of HSPCs related to quiescence and resistance to drugs and environmental stresses. At steady state, SP cells a...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2013.256
更新日期:2014-04-01 00:00:00
abstract::The chimeric fusion oncogene early B-cell factor 1-platelet-derived growth factor receptor-β (EBF1-PDGFRB) is a recurrent lesion observed in Philadelphia-like B-acute lymphoblastic leukemia (B-ALL) and is associated with particularly poor prognosis. While it is understood that this fusion activates tyrosine kinase sig...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2017.166
更新日期:2018-01-01 00:00:00
abstract::We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-alpha failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402996
更新日期:2003-08-01 00:00:00
abstract::Multidrug resistance (MDR) is one of the major obstacles to successful cancer chemotherapy. Since P-glycoprotein (P-gp) encoded by the MDR-1 gene plays a key role in MDR, many P-gp-specific monoclonal antibodies (MAbs) have been generated for characterization and analysis of P-gp. Among those antibodies, MRK16 has bee...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/sj.leu.2400658
更新日期:1997-07-01 00:00:00
abstract::Acute promyelocytic leukemia (APL) is a subtype of acute leukemia characterized by a unique t(15;17) translocation generating the PML/RARA fusion gene and hybrid oncoprotein. Besides its critical role in leukemogenesis, this genetic aberration serves as a disease-specific biomarker for rapid diagnosis and monitoring o...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/s41375-018-0219-5
更新日期:2018-08-01 00:00:00
abstract::Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2016.260
更新日期:2017-03-01 00:00:00
abstract::In this work we have mapped by double-label immunofluorescence the cellular distribution of integrins and their relationship with cytoskeletal proteins in normal and malignant monocytes. In normal monocytes, CD18 and CD11c are concentrated at specific adhesion sites, named podosomes, together with actin, vinculin, and...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1990-10-01 00:00:00
abstract::Novel approaches have been designed to treat leukemia based on our understanding of the genetic and biochemical lesions present in different malignancies. This meeting report summarizes some of the recent advances in leukemia treatment. Based on the discoveries of cellular oncogenes, chromosomal translocations, monocl...
journal_title:Leukemia
pub_type:
doi:10.1038/sj.leu.2403156
更新日期:2003-12-01 00:00:00
abstract::Different normal and malignant human B-cell populations were studied with a twofold aim: to define which cytokines are produced in vivo, and to assess the relationship between cytokine production and kinetic state. To analyse normal B-cells representative of different stages of activation and proliferation in vivo, we...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1992-02-01 00:00:00
abstract::The c-kit proto-oncogene encodes a receptor tyrosine kinase that is known to play a crucial role in mast cell growth and differentiation. In a human mast cell leukemia cell line (HMC-1), KitR was found to be constitutively phosphorylated on tyrosine, activated and associated with phosphatidylinositol 3-kinase (P13K) i...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1994-04-01 00:00:00
abstract::We analyzed nucleotide sequence and intraclonal diversity of the rearranged immunoglobulin heavy chain gene variable region (VH gene) of CD5+ and CD5- diffuse large B cell lymphoma (DLBCL) to clarify the cell origin of de novo CD5+ DLBCL. Ten cases of CD5+ DLBCL and 29 cases of CD5- DLBCL were analyzed. The frequencie...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402031
更新日期:2001-03-01 00:00:00
abstract::Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently based only on early response to chemotherapy. We investigated the prognostic implication of hyperactivation of NOTCH pathway resulting from mutations of NOTCH1 or FBXW7 in children with T-ALL enrolled in EORTC-CLG tria...
journal_title:Leukemia
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1038/leu.2010.205
更新日期:2010-12-01 00:00:00
abstract::The adult marrow hematopoietic stem cell biology has largely been based on studies of highly purified stem cells. This is unfortunate because during the stem cell purification the great bulk of stem cells are discarded. These cells are actively proliferating. The final purified stem cell is dormant and not representat...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/leu.2017.155
更新日期:2017-08-01 00:00:00
abstract::Bryostatin 1 is a macrocyclic lactone activator of protein kinase C which has displayed promising antileukemic potential in pre-clinical studies. We have assessed the effect of bryostatin 1 on the in vitro clonogenic response of leukemic myeloblasts obtained from 12 patients with acute non-lymphocytic leukemia to reco...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1991-05-01 00:00:00
abstract::The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype. Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL)...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403943
更新日期:2005-11-01 00:00:00
abstract::Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell death via Cereblon (CRBN)-dependent ubiquitylation and proteasome-dependent degradation of IKZF1 and IKZF3. A...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-019-0403-2
更新日期:2019-08-01 00:00:00
abstract::Identification of rearrangements in the immunoglobulin heavy chain (IgH), T cell receptor (TCR) and other genes assists in the classification of hemopoietic disorders. This study reviews a 5 year experience of genotyping as an assessment of clonality in a central referral laboratory. Patients were referred for assessm...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/sj.leu.2400678
更新日期:1997-06-01 00:00:00